Amino acids

AXIM® Biotechnologies Nutraceutical Division Announces Cannabinoid-Based Wellness Gum Product Line at Benzinga Cannabis Capital Conference

Retrieved on: 
Tuesday, October 22, 2019

(AXIM Biotech, AXIM or the Company) (OTCQB: AXIM), a world leader in cannabinoid research and development, announced today that its nutraceutical division, AXIM Wellness, has launched its flagship nutraceutical product line, AXIM Wellness Gum (Wellness Gum), at the Benzinga Cannabis Capital Conference in Chicago, IL.

Key Points: 
  • (AXIM Biotech, AXIM or the Company) (OTCQB: AXIM), a world leader in cannabinoid research and development, announced today that its nutraceutical division, AXIM Wellness, has launched its flagship nutraceutical product line, AXIM Wellness Gum (Wellness Gum), at the Benzinga Cannabis Capital Conference in Chicago, IL.
  • Wellness Gum PM formulated with 5 mg of CBD, 25 mg of full-spectrum hemp oil, melatonin, L-Tryptophan and vitamin B3.
  • We are excited for the launch of the Wellness Gum product line during the Benzinga Cannabis Capital Conference and look forward to discussing our new cannabinoid-based nutraceutical gum line with the cannabis community, said John W. Huemoeller II, Chief Executive Officer of AXIM Biotech.
  • AXIM also intends to continue expanding the reach of its Wellness Gum line across the nation through individual sales representatives.

OrganicEye Petitions USDA to Remove Carcinogen from Organic Food

Retrieved on: 
Wednesday, October 16, 2019

WASHINGTON, Oct. 16, 2019 /PRNewswire/ -- In an effort to remove cancer causing nitrites from deli-type and other processed meats labeled organic, the industry watchdog OrganicEye has petitioned the USDA's National Organic Standards Board (NOSB).

Key Points: 
  • WASHINGTON, Oct. 16, 2019 /PRNewswire/ -- In an effort to remove cancer causing nitrites from deli-type and other processed meats labeled organic, the industry watchdog OrganicEye has petitioned the USDA's National Organic Standards Board (NOSB).
  • At its public meeting next week, the NOSB will consider whether cured organic meats may continue to be processed with nonorganic celery powder, which contains high levels of nitrates.
  • The Organic Foods Production Act prohibits synthetic nitrate use in organic crop production and adding nitrates or nitrites in processing.
  • OrganicEye is also recommending that the Board remove the synthetic amino acid methionine from the list of allowed synthetic substances, no longer allowing it to be added to organic poultry feed.

Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium

Retrieved on: 
Wednesday, October 2, 2019

THE WOODLANDS, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from five posters highlighting XERMELO (telotristat ethyl) will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium (NANETS; October 3-5, Boston, MA).

Key Points: 
  • THE WOODLANDS, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from five posters highlighting XERMELO (telotristat ethyl) will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium (NANETS; October 3-5, Boston, MA).
  • XERMELO targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within metastatic neuroendocrine tumor (mNET) cells.
  • Lexicon has granted Ipsen an exclusive royalty-bearing right and license to commercialize XERMELO outside of the United States and Japan.
  • Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Global Lysine Market Trends, CAGR, Growth Analysis and Forecast Report up to 2023: Radiant Insights, Inc

Retrieved on: 
Wednesday, October 2, 2019

SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- The Global Lysine Market is anticipated to grow at a significant CAGR during the forecast period.

Key Points: 
  • SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- The Global Lysine Market is anticipated to grow at a significant CAGR during the forecast period.
  • North American lysine market dominates the global share due to presence of manufacturing sector and agricultural practices at large.
  • The Global Market for lysine to 2023 offers detailed coverage of lysine industry and presents main market trends.
  • Access 134 page research report with TOC on "Global Lysine Market" available with Radiant Insights, Inc. @: https://www.radiantinsights.com/research/global-lysine-market-outlook-20...
    Analysis of the lysine market including revenues, future growth, market outlook
    Analyzes the end user markets including growth estimates.

Global Lysine Market Trends, CAGR, Growth Analysis and Forecast Report up to 2023: Radiant Insights, Inc

Retrieved on: 
Wednesday, October 2, 2019

SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- The Global Lysine Market is anticipated to grow at a significant CAGR during the forecast period.

Key Points: 
  • SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- The Global Lysine Market is anticipated to grow at a significant CAGR during the forecast period.
  • North American lysine market dominates the global share due to presence of manufacturing sector and agricultural practices at large.
  • The Global Market for lysine to 2023 offers detailed coverage of lysine industry and presents main market trends.
  • Access 134 page research report with TOC on "Global Lysine Market" available with Radiant Insights, Inc. @: https://www.radiantinsights.com/research/global-lysine-market-outlook-20...
    Analysis of the lysine market including revenues, future growth, market outlook
    Analyzes the end user markets including growth estimates.

Altavant Sciences to Present New Rodatristat Ethyl Clinical Biomarker and Safety Findings at the ERS International Congress 2019

Retrieved on: 
Tuesday, September 24, 2019

The poster will be presented on Tuesday, October 1 at 12:50 CEST and will be available on the Publications page of the Altavant website following its presentation at the congress.

Key Points: 
  • The poster will be presented on Tuesday, October 1 at 12:50 CEST and will be available on the Publications page of the Altavant website following its presentation at the congress.
  • Rodatristat is a tryptophan hydroxylase (TPH) inhibitor designed to reduce the body's peripheral production of serotonin.
  • Altavant is currently evaluating rodatristat ethyl in the ELEVATE1 proof-of-concept Phase 2a study in patients with PAH.
  • Rodatristat ethyl is currently being evaluated in the ELEVATE1 Phase 2 Study for patients with PAH.

Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome

Retrieved on: 
Monday, September 16, 2019

GABA is the main inhibitory neurotransmitter in the brain, known to be deficient in animal models of Rett syndrome.

Key Points: 
  • GABA is the main inhibitory neurotransmitter in the brain, known to be deficient in animal models of Rett syndrome.
  • Excitatory-inhibitory imbalances postulated in many neurologic disorders, including Rett syndrome, have been linked to imbalances between Glutamate and GABA1,2.
  • Therefore, the DSMB issued a positive recommendation for the continuation of the Phase 2 Rett syndrome study without any modifications.
  • The ANAVEX2-73 (blarcamesine) Phase 2 Rett syndrome study design includes genomic biomarkers identified in the ANAVEX2-73 (blarcamesine) Phase 2a AD study.

ERYTECH to Host Second Quarter 2019 Conference Call and Business Update

Retrieved on: 
Wednesday, September 11, 2019

LYON, France, Sept. 11, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2019 conference call and webcast onWednesday, September 18, 2019, at2:30 PM CEST/8:30 AM ESTto discuss operational highlights.

Key Points: 
  • LYON, France, Sept. 11, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2019 conference call and webcast onWednesday, September 18, 2019, at2:30 PM CEST/8:30 AM ESTto discuss operational highlights.
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is also developing erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers.
  • ERYTECH is part of the CACHealthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Doc Parsley relaunches the Sleep Remedy with an improved formula and new flavor

Retrieved on: 
Monday, August 26, 2019

Doc Parsley's Sleep Remedy is a natural sleep solution crafted to help overcome the most common nutritional deficiencies that can interfere with deep, restorative sleep.

Key Points: 
  • Doc Parsley's Sleep Remedy is a natural sleep solution crafted to help overcome the most common nutritional deficiencies that can interfere with deep, restorative sleep.
  • In line with the formula creator's philosophy of helping to change the way people sleep by replenishing nutritionally and stress-induced deficiencies, Sleep Remedy has been updated to include more ingredients to fight poor sleep effectively.
  • This is where Dr. Kirk Parsley is looking to change the narrative with Sleep Remedy that has already helped many find restorative sleep.
  • The new Sleep Remedy contains the legacy formula Melatonin, L-tryptophan, 5-HTP, Magnesium (Magtein), Vitamin D3 as well as new players, GABA and L-theanine, and Phosphatidylserene.

Study Finds American Grown Pistachios Contain Melatonin

Retrieved on: 
Friday, August 9, 2019

The study was significant due to the fact it showed pistachios contain relatively high levels of melatonin compared to other foods and that researchers identified two protective bioactive compounds, lunasin and the Bowman-Birk Inhibitor, which have anti-inflammatory, anti-angiogenic activity that may help manage type 2 diabetes.

Key Points: 
  • The study was significant due to the fact it showed pistachios contain relatively high levels of melatonin compared to other foods and that researchers identified two protective bioactive compounds, lunasin and the Bowman-Birk Inhibitor, which have anti-inflammatory, anti-angiogenic activity that may help manage type 2 diabetes.
  • In this study, melatonin was extracted from raw and roasted pistachios grown in the United States.
  • According to Losso, pistachios contain certain phenolics which can reduce the breakdown of tryptophan to toxic compounds so that it is converted to melatonin.
  • Additionally, Yeboah-Awudzi, recommends pistachios as a natural food option worth considering if anyone is looking to increase their melatonin intake.